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Abstract Neuroinflammation is a process characterised by
drastic changes in microglial morphology and by marked
upregulation of the 18-kDa translocator protein (TSPO) on
the mitochondria. The continual increase in incidence of
neuroinflammation and neurodegenerative diseases poses a
major health issue in many countries, requiring more
innovative diagnostic and monitoring tools. TSPO expression
may constitute a biomarker for brain inflammation that could
be monitored by using TSPO tracers as neuroimaging agents.
From medical imaging perspectives, this review focuses on
the current concepts related to the TSPO, and discusses
briefly on the status of its PET imaging related to neuro-
inflammation and neurodegenerative diseases in humans.
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Introduction
Medical imaging—from morphome to molecules
The spectrum of medical imaging extends from morphol-
ogy, over function, to molecules. X-ray based imaging
modalities [traditional X-ray and computed tomography
(CT)] primarily deal with anatomy and patterns, whereas
radionuclide imaging, including positron emission tomog-
raphy (PET) and single photon emission computed tomog-
raphy (SPECT), assess function and physiology [1] (Fig. 1).
From the medical viewpoint, clinical molecular imaging
can be broadly defined as the in vivo non-invasive visual-
isation, characterisation and measurement of disease pro-
cesses at the molecular or cellular level using specific
imaging probes [2]. It sets forth to detect the biochemical
changes underlying diseases rather than to image the
macroscopic structural results of pathological processes.
The current trend of new medical imaging scanner design
and development is based on multimodel and multiparametric
approaches. Indeed PET and its hybrid imaging modalities
PET/CT, and beforelongmagneticresonance imaging (MRI)/
PET, are changing the way we practice medicine. To date,
PET/CT is currently a diagnostic imaging technique used in
many hospitals worldwide to provide services for patients,
especially in the fields of oncology, neuroscience and
cardiology [3]. In spite of the recent advances of molecular
and imaging techniques, there is still a gap between basic
biomedical research and its clinical applications. Nowadays
clinical PET tracer still mainly refers to the commercially
available 2-deoxy-2-[
18F]fluoro-D-glucose ([
18F]FDG). The
impact of PET and its hybrid systems to medicine is limited
by the worldwide shortage of radiochemistry facilities to
produce novel PET tracers to detect various pathophysiolog-
ical mechanisms or to specify diagnosis or even theranostics
of neurodegenerative diseases.
With the launching of new hybrid imaging systems like
MRI/PET, radiologistswill expecttoplayanevenmoreactive
role in directing development of the rapidly evolving field of
medical imaging. Although not all practicing radiologists will
engage in the field of research and sciences, it is worthwhile
that they keep abreast of recent development of PET tracers in
the areas as diverse as oncology, cardiology, metabolic
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DOI 10.1007/s13244-011-0128-xdiseases and neurology. In this tutorial article, we review the
current concepts related to the pathophysiology of neuro-
inflammation and neurodegenerative diseases and give a
glance on the status of PET imaging of 18-kDa translocator
protein (TSPO) tracers in neuroinflammation of the living
brain, with the aim of providing a basis for future discussions
on the development of TSPO tracers for the diagnosis and
therapy of neurodegenerative diseases.
PET is intrinsically quantitative for 3D neuroreceptor
imaging
PET is an imaging technique in which molecular tracers
labelled with positron emitters are injected into the human
body to track biochemical and physiological processes [3].
Imaging agents used for PET are radioactive probes
emitting positively charged anti-electrons (positrons). The
positron travels a short distance (less than a millimetre)
before it annihilates with any electron to give two photons
of 511 keV travelling under a mutual angle of 180°. It is
this pair of coincident high-energy photons that underlies
the PET principle allowing in vivo quantitative three-
dimensional (3D) imaging through coincident detection
using a gantry of multiple detectors around the patient
(Fig. 2). The genuine strength of this powerful molecular
imaging modality is its picomolar sensitivity and the
possibility of quantitative imaging of in vivo binding to
the specific neuroreceptors like TSPO, dopamine receptors
and serotonin receptors. PET allows a quantitative 3D
reconstruction of the in vivo radioactivity levels of the
isotope administrated to a patient [4] (Table 1). It can
deliver quantitative measures of biochemical parameters
such as the TSPO density in living brain. In vivo
assessment of tracer binding to a receptor site is based on
the principles of receptor pharmacology [5]. The success of
in vivo receptor measurements is predetermined by the
understanding of the underlying biological system and by
applying the optimal pharmacological model. When done
properly, neuroreceptor PET studies can provide useful
contributions to clinical studies and also for drug discovery
and development.
Brain as an “immune privileged”organ: to be or not to be?
Neuroinflammation denotes central nervous system (CNS)-
specific, inflammation-like glial responses that do not
reproduce the classic characteristics of inflammation in the
periphery but which may engender neurodegenerative
events [6]. A neurodegenerative disease is defined as a
progressive irreversible deterioration of the motor, sensory
or cognitive functions associated with neuronal loss.
Traditional concepts have tended to focus attention on pure
neurodegenerative or inflammatory mechanisms, neglecting
an integrated perspective. These two previously distinct
areas of neuroscience are in fact highly related. Since 1873
the brain was classified as an “immune privileged” organ
because it seemed to be not affecting by immune responses
or inflammation. The organ does not reproduce the classic
characteristics of inflammation as in other parts of body.
However, there is a recent shift in the fundamental concept
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Fig. 2 PET principle: imaging agents used for PET are radioactive
probes emitting positively charged anti-electrons (positrons). The
positron travels a short distance (∼1–3 mm) before it annihilates with
any electron to give two photons of 511 keV travelling under a mutual
angle of 180°. It is this pair of coincident high energy photons that
underly the PET principle allowing in vivo quantitative 3D imaging
through coincident detection using a gantry of multiple detectors
around the patient
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Fig. 1 Medical imaging ranges from morphology to function, down
to molecules. Clinical molecular imaging is broadly defined as the in
vivo visualisation and measurement of disease processes at the cellular
and molecular level. It is an emerging technology that allows the
characterisation of interactions between molecular probes and biolog-
ical targets
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related inflammatory reactions in the brain [7]. It indicates a
more active role of neuroinflammation in the pathophysi-
ology of progressive neurodegenerative disorders. The
responses and actions of microglial cells and astrocytes in
thebrainhaveaninflammation-likecharacter.Thesecellsplay
major roles in neuroinflammation and neurodegenerative
diseases and they are involved in many complex cellular
responses [8]. Many pathological events can trigger neuro-
inflammation and the primary insult can be infective,
degenerative, metabolic or ischaemic. For example, acute
inflammation is associated with trauma, stroke and enceph-
alitis, whereas multiple sclerosis (MS), Alzheimer’sd i s e a s e
(AD), Parkinson’s disease (PD), Huntington’s disease (HD),
and amyotrophic lateral sclerosis are some of those
conditions involving chronic inflammation. Inflammation
has been identified as an important factor in primary
neurodegenerative disorders. In the past, the associated
inflammatory glial responses in these diseases had often
been regarded as non-specific “reactive gliosis” that
deserved no further significance. This viewpoint might
be related to insensitivity of the conventional anatomical
imaging modalities, including MRI, to grey matter
changes such as plaques, gliosis or subtle atrophy.
However, several researchers have discovered that
primary neurodegenerative disorders and neuroinflam-
mation are intermingled by immune responses [7, 9]
(Fig. 3). Collateral neuronal destruction and myelin
damage can occur in the course of neuroinflammation
and neurodegeneration [7]. For example, the decline of N-
acetyl-aspartate (NAA) levels on MR spectroscopy has
been shown to be an indicator for neuronal damage in
neurodegenerative diseases such as MS [10]. In the light
of these findings, both purely inflammatory and neurode-
generative pathologies are controlled and regulated by the
common molecular mechanism with collateral neuronal
damage [7]. Initially divergent events such as ischaemia,
peroxysomal dysfunction or amyloid beta protein (Aβ)
deposition clearly initiate involvement of the immune
system, which in turn interacts with the nervous system
and ultimately sets the pace of progressive tissue damage.
Microglial activation fans the flame
in neuroinflammation
Microglia are the critical convergence point for the many
diverse triggers in orchestrating the activity of other
immune cells in the brain [6]. These cells are derived from
the monocytic lineage display high sensitivity to different
types of CNS injury [11]. During neuroinflammation,
microglia undergo drastic changes in their morphology,
migrate towards the lesion site, proliferate, and produce
neurotoxic factors such as proinflammatory cytokines and
reactive oxygen species. Stroke, hypoxia, and trauma
compromise neuronal survival and indirectly trigger neuro-
inflammation as microglia become activated in response to
insult in an attempt to limit further injury. A mild
autoimmune reaction with microglial activation can have
neuroprotective function after CNS injury [9]. An acute
insult may trigger oxidative and nitrosative stress, it is
typically short lived and unlikely to be detrimental to
long-term neuronal survival. On the contrary, chronic
neuroinflammation is a longstanding and often self-
perpetuating response that persists long after an initial
injury or insult. It includes not only longstanding
activation of microglia but also subsequent release of
inflammatory factors. In chronic inflammation, immune
response can be full-blown, including the activation of
microglia, and damage the brain tissues by autoimmu-
nogens [12]. That means activated microglia can be either
friends or foes to neighbouring neurons. It is not yet clear
how to manipulate them to minimise their damaging
effects.
Overexpressed TSPO on the mitochondral membrane
TSPO, formerly known as peripheral benzodiapzepine
receptor (PBR), is a ubiquitous high affinity cholesterol
transporter found primarily in the outer mitochondrial
membrane of steroid-synthesising cells. To a lesser extent,
the protein is also found in the cell nucleus and plasma
membrane. The new name was adopted in 2006 in view of
Table 1 Comparison of radionuclide imaging and MRI as molecular imaging systems [28]
Imaging modality Physiological parameter Sensitivity Spatial resolution (mm) Minimal amount of tracer
(or contrast agent) used
PET Biochemical pM 1–5n g
SPECT Biochemical pM 1–10 ng
MRI Proton density μM 0.1–1
a μgt om g
ppico (10
−12), µmicro (10
−6), nnano (10
−9)
a1-3 mm for fMRI and 5–10 mm for MRS
Insights Imaging (2012) 3:111–119 113new insights into its structure and molecular functions.
Although TSPO is found in many tissue types, it is
expressed at the highest levels under normal conditions in
tissues that synthesise steroids [13]. It has high level of
expression in organs such as adrenals, kidneys, lungs and
spleen [14]. The TSPO is also found in many other regions
of the body, including human iris, ciliary body, heart, liver,
testis, blood cells and brain. The TSPO is expressed at low
levels primarily on microglia in healthy brain. It is
expressed by the mitochondria of activated microglial cells
in response to a variety of pathogens and insults [12].
TSPO can also be expressed in macrophage in inflamma-
tory tissues associated with tumours [15]. It is significantly
upregulated in breast, prostate, colon and brain cancers with
protein expression linked to cancer progression and poor
survival rates [13]. TSPO is a part of the mitochondrial
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Fig. 3 Collateral neuronal dam-
age is clearly inherent to primary
neuroinflammatory diseases, and
neuroinflammation is a likely
consequence of primary neuro-
degeneration. a In primary
degenerative diseases like AD
and in stroke, a non-immune-
mediated CNS injury is initiated.
Immune response cells, predom-
inantly local microglia,
marcophages and lymphocytes,
are involved in the degenerative
processes and elicit a secondary
inflammatory reaction, which
sets the pace of progressive
neuronal damage. Some of these
mechanisms might also occur at
certain stages of MS. b In pri-
mary inflammatory CNS disease
such as MS, activated immune
cells—namely, microglia, macro-
phages and lymphocytes—attack
a common target antigen of the
brain, typically part of the myelin
sheath. Demyelination, axonal
transection and neuronal death
can occur during the immune
response. The loss of myelin
might result in secondary axonal
transection (outside-in damage)
or, vice versa, death of an axon
can lead to secondary demyelin-
ation (inside-out damage).
Some of these sequences consti-
tute the pathogenesis of
diseases like AD
114 Insights Imaging (2012) 3:111–119permeability transition pore (MPTP). The MPTP consists of
at least three different subunits on the mitochondrial outer
membrane, including the isoquinolone binding protein of
18 kDa (TSPO), a voltage-dependent anion channel of
32 kDa (VDAC) and an adenine nucleotide transporter of
30 kDa (ANT) [16] (Fig. 4). It contains inner and outer
membrane contact sites to facilitate the passage of
lipophilic molecules across the intermembrane space. The
minimal functional unit or the binding site, however, is the
18-kDa protein, which mainly consists of five transmem-
brane domains. Its importance does not depend only on
ligand binding but also on the subsequent effects of binding
[8]. TSPO has four main functions: (1) cholesterol binding
and transport into mitochondria, a key function in steroido-
genesis and bile salt synthesis, (2) protein import for
membrane biogenesis, and directly or indirectly for other
cellular functions including apoptosis, cell proliferation,
differentiation, and anion transport, (3) porphyrin binding
and transport for heme synthesis, and (4) regulation of
mitochondrial function and immune regulation [13, 16].
Although research suggests that there are multiple TSPO
binding sites, the nature of these sites and their functional
significance is still obscured [17]. It is not exactly known
what the endogenous ligands of TSPO are but some
propose they can be cholesterol, diazepam-binding inhibitor
(DBI), a neuropeptide, or porphyrins [9]. It is possible that
TSPO polymerisation is associated with steroidogensis and
it results in a conformational change to the TSPO binding
sites [17].
In the CNS, TSPO ligands have been found to stimulate
synthesis of neurosteroids involved in diverse functions,
from regulation of apoptosis to reduction of anxiety via
modulation of GABAA receptor [16]. The TSPO expression
is low in normal brain but it is upregulated in the brain at
sites of injury and inflammatory tissues associated with
tumour. The molecular mechanisms underlying these con-
ditions are unknown, although some factors, such as
reactive oxygen species, interleukin 1 and tumour necrosis
factor (TNF)α, may play a role. Local TSPO overexpres-
sion in response to damage makes it a potentially ideal and
sensitive marker for the detection of subtle changes in the
region of brain insult (Fig. 5).
[
11C]PK11195: the workhorse for TSPO imaging
and its limitations
PK11195 [1-(2-chlorophenyl)-N-methyl-N-(1-methyl-
propyl)-3-isoquinoline carboxamide] is the first non-
benzodiazepine and selective TSPO ligand labelled with
carbon-11. It was discovered in 1984 and named by a
French company, Pharmuka [18]. It remains most widely
used in TSPO PET imaging with nanomolar binding
affinity and it is the prototypical reference [19]. [
11C]
PK11195 has been used in many human CNS studies,
including Rasmussen’s encephalitis, MS, AD, PD, amyo-
trophic lateral sclerosis, HD, HIV, herpes encephalitis, and
neuropsychiatric disorders such as schizophrenia [16].
Studies found increased binding of [
11C]PK11195 in
corresponding MR regions of focal gadolinium-enhanced
lesions and normal-appearing white matter (NAWM) in MS
patients [20] .B r a i na t r o p h y ,c o r r e l a t i n gw i t hd i s e a s e
duration and disability of MS is directly related to [
11C]
PK11195 uptake, NAWM and inflammatory-related T2
hyperintense lesions [20, 21]. A study also showed an
Radiolabelled
TSPO tracer
18 kDa TSPO VDAC
ANT
Porphyrin binding 
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Regulation of 
membrance
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Fig. 4 TSPO structures and functions. It is a hetero-oligomeric
complex and consists of at least three different subunits, including the
isoquinolone binding protein of 18-kDa TSPO, a voltage-dependent
anion channel (VDAC) and an adenine nucleotide transporter (ANT).
It contains inner and outer membrane contact sites to facilitate the
passage of lipophilic molecules across the intermembrane space. The
minimal functional unit or the binding site, however, is the 18-kDa
protein. TSPO has four main functions: (1) cholesterol binding and
transport into mitochondria, a key function in steroidogenesis and bile
salt synthesis, (2) protein import for membrane biogenesis, and other
cellular functions including apoptosis, cell proliferation, and differen-
tiation, (3) porphyrin binding and transport for heme synthesis, and (4)
regulation of mitochondrial functions
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11C]PK11195 in MS patients
during acute relapse [21]. Taken together, these studies
suggest that microglial activation is of central importance in
the pathophysiology of MS and can be visualised with PET
using TSPO tracers.
In cerebral infarction, [
11C]PK11195 is a useful tool to
investigate acute neuroinflammatory changes related to
cerebral infarct and could be beneficial in the evaluation
of neuroprotective regimens related to microglial deregula-
tion [22]. Aβ is known as a pathological substance in AD
and is assumed to coexist with a degree of activated
microglia in the brain. A few studies showed in vivo
microglial activation in the brain of patients with mild to
moderate AD using PET with [
11C]PK11195, but the role is
limited in severe AD [12, 23]. Increased microglial
activation has been observed in patients with HD and
presymptomatic carriers by [
11C]PK11195 PET imaging
[24]. In HD, the degree of microglial activation in the
striatum has been found to correlate with D2 receptor
dysfunction using PET with [
11C]raclopride [25]. More
recent studies suggest neuroinflammation might have a
crucial role in neuropsychiatric disorders such as schizophre-
nia [26, 27]. Although there was large individual variation in
humans, binding of [
11C]PK11195 was increased in brain
areas corresponding to different pathological processes in
ongoing or recent clinical deficits. TSPO imaging with PET
might provide insight into the process beyond the realm of
traditional neuroimaging techniques.
Although it is well established that [
11C]PK11195 shows
increased uptake in a wide array of neurodegenerative
disorders, it suffers from unresolved methodological and
kinetic issues. There is low sensitivity and a limited
capacity to quantify subtle TSPO expression in vivo.
Relatively low receptor affinity could lead to low binding
potential, which results from substantial binding of the
tracer to other parts of the body. It suffers from high plasma
protein binding and high non-specific binding likely related
to high lipophilicity. The more lipophilic molecule is
undesirable not only for slowing passive brain entry but
also for increasing high non-specific binding to brain fats
and protein. Relatively poor penetration of the blood brain
barrier (BBB) and low brain uptake also lead to poor
signal-to-noise ratio on PET imaging. Also, the lack of
sensitivity and specificity and highly variable kinetic
behaviour of [
11C]PK11195 have precluded the develop-
ment of a standard quantitative method of analysis [8, 14].
Without an on-site cyclotron facility, the short half-life of
carbon-11 (t1/2=20.38 min) also limits PET imaging using
[
11C]PK11195 in routine clinical practice.
Current trend of novel potential tracers
In the light of the limitations of [
11C]PK11195, many
groups worldwide are actively engaged in a search for new
radiotracers with improved capacities to image and quantify
TSPO Imaging Strategy
MICROGLIAL
ACTIVATION &
TSPO
OVEREXPERSSION 
RADIOLABELLED
TSPO LIGAND 
IN VIVO PET
IMAGING 
Fig. 5 In vivo TSPO imaging by PET. PET imaging of microglial cells
in vivo involves utilising ligands labelled with
11Co r
18F radioisotopes
that bind translocator protein (TSPO) expressed on the outer mitochon-
drial membrane in microglia. The radioisotope undergoes positron
emission decay underlying the principle of PET imaging
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comprehensive reviews have been published on TSPO
imaging [8, 9, 14, 16, 28]. Schweitzer et al. [16] and
Rupprecht et al. [9] offer more details on the updated trend
of TSPO radiotracers development.
TSPO radiotracers can be basically subdivided into
seven chemical classes. Extensive research during recent
years has led to the development of more than 50 new
TSPO tracers [8, 14, 16, 29]. New tracers that used in
human studies include [
11C]DAA1106, [
18F]FEDAA1106,
[
11C]PBR28, [
11C]vinpocetine, [
11C]AC-5216, [
11C]
DPA713 and [
18F]DPA714 [30–38] (Table 2). The studies
in humans are at their initial stages with sporadic findings.
From the glimpse of information, [
11C]DAA1106, [
18F]
FEDAA1106, and [
11C]PBR28 have shown significantly
increased binding in living brain. The binding potential of
[
11C]vinpocetine is higher than [
11C]PK11195 in MS
patients. [
18F]DPA-714, a close analogue of DPA-713, is
also a promising PET tracer and has recently demonstrated
high affinity for the TSPO with better uptake and binding
potential than [
11C]PK11195 [19, 38]. More recent studies
show [
11C]SSR180575, the first TSPO radioligand based
on an indoleacetamide scaffold, has a better capacity than
[
11C]PK11195 to distinguish inflammatory tissue from
healthy brain tissue [39, 40]. Discrepancies are found
between the results of the binding affinities of different
new TSPO radiotracers, and they showed heterogeneity in
binding potentials in humans [9, 16, 41, 42].
Most of the new TSPO tracers are, however, still in the
infancy of investigation and some show mixed-affinity
binding in human [41, 42]. Many research efforts in
preclinical studies are aimed at the following key areas:
Table 2 Examples of new potential PET tracers for TSPO imaging in clinical studies
PET tracer Chemical class Diseased/healthy subjects Findings
[
11C]DAA1106 Phenoarylacetamides [6] AD, ALS, FTD, MS, CI Higher binding affinity compared
with PK11195 [33, 43]
a
[
11C]vinpocetine Vina alkaloids[4] MS, healthy subjects Higher BP but potential different binding
sites as PK11195 [44–46]
[
18F]FEDAA1106 Phenoarylacetamides [6] Healthy subjects Match known patterns of TSPO distribution [47]
a
[
11C]PBR28 Phenoarylacetamides [6] Healthy subjects Good agreement of pattern in TSPO distribution [35]
a
[
11C]AC-5216 Oxodihydropurines [5] Healthy subjects Match known patterns of TSPO distribution [36]
a
[
11C]DPA-713 Pyrazolo-[1,5-a]-pyrimidines [7] Healthy subjects Potentially higher binding affinity than PK11195 [37]
a
[
18F]DPA-714 Pyrazolo-[1,5-a]-pyrimidines [7] Healthy subjects Potentially higher binding potential in brain [38]
AD Alzheimer’s disease, ALS amyotrophic lateral sclerosis, MS multiple sclerosis, FTD frontotemporal dementia, CI cerebral infarction
aMixed-affinity binding in human brain
BBB Blood Brain
TSPO
E. T.
E.T.
Tf Tb
Mf Mb
Tf
Tnb
Tsb
Mf Mnb
Fig. 6 Schematic representation
of TSPO radiotracer in the brain
shows the fates of TSPO radio-
tracer and its radiometabolites
passing through the brain-blood
barrier (BBB). Radiotracer design
for TSPO for the brain aims to
achieve optimal passive diffusion
across the BBB without impedi-
ment by efflux transporters (E.T.)
to give a high specific binding
(indicated by red circles). Many
research efforts are aimed at (1)
radiotracer metabolic stability (no/
less radiometabolites), (2) high
binding potential (high specific
binding), (3) ligand-receptor ki-
netics (to optimise kinetic model-
ling), and (4) quantitative methods
(Tradiotracer, Mradiometabolite, f
free, bbound, nbnon-specific
binding, sbspecific binding)
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(BP), (3) ligand-receptor kinetics, and (4) quantitative
methods. The new TSPO tracer must show high affinity
and selectivity for the receptor. Ideally, a PET radiotracer
should enter the brain and interact selectively with its target
in the absence of troublesome radiometabolites. Practically,
potential problems related to radiometabolites of the tracer
must be limited through effective radiotracer design. It is
essential for accurate in vivo measurement of the density of
a target protein like TSPO. Binding potential measures,
obtained with PETand a specific radiotracer, are considered
to be proportional to the receptor density in vivo and high
BP is crucial for TSPO quantification [5]. Suitable brain
pharmacokinetics in relation to radiolabel half-life with
observable brain uptake and washout kinetics is also
desirable for measuring ligand-receptor interaction (Fig. 6).
Perspectives
There is accumulating evidence that neuroinflammation plays
a crucial role in the development and progression of many
neurodegenerative disorders such as MS, AD and HD.
Collateral neuronal damage is clearly inherent to primary
neuroinflammation, and neuroinflammation is a likely sequel
of primary neurodegenerative diseases. It is important to
understand the mechanisms that initiate neuroinflammation
and neurodegeneration. Many questions remain regarding the
use of TSPO tracers as diagnostic tools to assess activation of
microglia. Overexpressed TSPO constitutes an important
target for the detection or novel treatment of neuroinflamma-
tion and neurodegenerative disorders. The concept of multiple
TSPO binding sites, variable conformational states of the
protein and mixed binding affinity in living brain needs to be
addressed when developing new PET TSPO radio-
tracers. Provided the broad spectrum of putative appli-
cations of TSPO ligands, further studies are eagerly
awaited. With further development of potential tracers
by better understanding of the protean nature of the
receptor in healthy and diseased brain, PET imaging of
the TSPO could offer a non-invasive modality for early
diagnosis and theranostics of CNS diseases in ways
beyond the scope of conventional imaging techniques.
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